Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06244485 · ClinicalTrials.gov registry record · Phase 1

A Study of Valemetostat Tosylate in Combination With DXd ADCs in Subjects With Solid Tumors

A Phase 1 study of Advanced Solid Tumor, sponsored by Daiichi Sankyo.

Recruiting
Registry status
Phase 1
Development phase
210
Enrollment target
20
Study locations

NCT06244485 is a Phase 1 study of Advanced Solid Tumor that is actively recruiting participants, run by Daiichi Sankyo. The registered enrollment target is 210 participants, roughly in line with the 192-participant average among 189 other Advanced Solid Tumor trials with a reported enrollment target. The trial reports 20 study locations across 13 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06244485, a Phase 1 study of Advanced Solid Tumor, is actively recruiting participants, sponsored by Daiichi Sankyo.

RECRUITING
Registry status
Phase 1
Development phase
210 participants
Enrollment target
20
Study locations

Study Summary

This study will evaluate the safety, tolerability, and efficacy of valemetostat tosylate in combination with DXd ADC in patients with advanced solid tumors.

Conditions Studied

Advanced Solid Tumor

Interventions

  • DRUG Dato-DXd
  • DRUG T-DXd
  • DRUG Valemetostat tosylate

Study Locations (20)

California

  • City of Hope At Orange County Lennar Foundation Cancer Center - Irvine
  • Valkyrie Clinical Trials - Los Angeles
  • Sharp Memorial Hospital - San Diego

Texas

  • Mary Crowley Cancer Research Centers - Dallas
  • Ut Southwestern Medical Center - Dallas
  • University of Texas M. D. Anderson Cancer Center - Houston

Florida

  • Brcr Medical Center, Inc Dba Boca Raton Clinical Research - Plantation
  • H. Lee Moffitt Cancer Center and Research Institute, Inc - Tampa

New York

  • Memorial Sloan-Kettering Cancer Center (Mskcc) - New York - New York
  • Clinical Research Alliance - Westbury

Virginia

  • Inova Schar Cancer Institute - Fairfax
  • Next Virginia - Fairfax

Hawaii

  • University of Hawaii At Manoa - Honolulu

Illinois

  • University of Chicago Medical Center - Chicago

Massachusetts

  • Dana-Farber Cancer Institute - Boston

Trial Details

FieldValue
Enrollment Target 210 participants
Start Date 2024-02-16
Est. Completion 2028-11-01
Phase Phase 1

Sponsor

Daiichi Sankyo

236 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT06244485

The ClinicalTrials.gov registry entry for NCT06244485 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 210 participants, a figure that helps gauge the scale of data the investigators plan to collect, roughly in line with the 192-participant average among 189 other Advanced Solid Tumor trials with a reported enrollment target. The listed sponsor is Daiichi Sankyo, which has 236 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Advanced Solid Tumor appearing as the primary indexed condition, and to 3 interventions - of which Dato-DXd is the first listed.

NCT06244485 reports 20 study locations spanning 13 distinct geographic areas - top geographies include California, Texas, Florida.

Frequently Asked Questions

What is clinical trial NCT06244485 about?

NCT06244485 is a clinical study titled "A Study of Valemetostat Tosylate in Combination With DXd ADCs in Subjects With Solid Tumors". This study will evaluate the safety, tolerability, and efficacy of valemetostat tosylate in combination with DXd ADC in patients with advanced solid tumors.

What is the current status of trial NCT06244485?

This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 210 participants. The study started on 2024-02-16. Estimated completion is 2028-11-01.

What conditions does trial NCT06244485 study?

This clinical trial studies the following conditions: Advanced Solid Tumor.

What interventions are being tested in trial NCT06244485?

The interventions under investigation include: Dato-DXd (DRUG), T-DXd (DRUG), Valemetostat tosylate (DRUG).

Who is sponsoring clinical trial NCT06244485?

This trial is sponsored by Daiichi Sankyo, which has 236 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06244485 being conducted?

This trial has 20 study locations across California, Florida, Hawaii, Illinois, Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Advanced Solid Tumor

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Advanced Solid Tumor

All registered trials for this condition

California

All trials with a study site in California

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.